• Native-MS Maps Proteoform-Specific Drug Interactions

  2026-09-26

  Lutomski and colleagues developed a native mass-spectrometry approach to release membrane proteins and complexes directly from retinal rod-disc membranes, then characterize their proteoforms and interactions. The work links lipid and other protein modifications to assembly and ligand binding, including distinct interactions of vardenafil and sildenafil with retinal PDE6—an important distinction from studying their intended PDE5 target.

• GW 4869 in Exosome and Osteogenesis Research

  2026-09-25

  GW 4869 hydrochloride hydrate is a cell-permeable neutral sphingomyelinase inhibitor used to investigate ceramide-dependent signaling and extracellular-vesicle release. In BMSC osteogenesis experiments, it can serve as a proposed perturbation tool for testing whether vesicle output contributes to lithium-associated Wnt10a signaling, but the cited lithium study did not test GW 4869.

• From Peptide to Phenotype: Translating CCK-8 Biology

  2026-09-25

  Sulfated CCK-8 can connect receptor pharmacology to measurable behavior, but interpreting that connection requires careful attention to species, dose, formulation, and assay design. A zebrafish study offers a useful benchmark—and a framework for translating Cholecystokinin octapeptide ammonium experiments without overstating what one model can show.

• CDK9 inhibitor A3294: Practical Workflow Guide

  2026-09-24

  CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for investigating CDK9-dependent transcription elongation and P-TEFb function. It is not a broad-spectrum CDK tool, and its reported viability and HIV-1 assay findings should be treated as context-specific rather than guarantees for other cells or protocols.

• NF-κB–Apaf1 Signaling in Septic Acute Kidney Injury

  2026-09-24

  The study identifies an NF-κB/Apaf1/caspase-9 pathway that suppresses autophagy while promoting tubular inflammation and apoptosis in experimental septic acute kidney injury. Genetic and pharmacologic perturbations support the pathway’s role in injury models, while leaving important questions about clinical relevance and upstream intervention unanswered.

• Adamtsl3, MMP9, and Adult Cortical Plasticity

  2026-09-23

  The study identifies Adamtsl3 as a parvalbumin-interneuron regulator of perineuronal-net integrity, acting in part through MMP9 regulation. Mouse experiments connect Adamtsl3 loss to reduced nets and renewed adult visual-cortical plasticity, while pharmacological rescue supports MMP9 as a relevant pathway for follow-up research.

• Adenosine Triphosphate (ATP) in Metabolic Research

  2026-09-23

  Adenosine Triphosphate (ATP) is a nucleotide that supports phosphate transfer, cellular metabolism, and extracellular purinergic receptor signaling. This article connects ATP handling with the 2025 discovery that TCAIM regulates OGDH protein abundance and mitochondrial metabolism.

• GW 4869: Exosome Workflow for Wnt10a Studies

  2026-09-22

  GW 4869 enables causal testing of neutral sphingomyelinase-dependent exosome production, ceramide signaling, and intercellular communication. This workflow translates lithium-engineered BMSC exosome findings into practical dose-finding, cargo-validation, and troubleshooting strategies.

• hly Deletion Reshapes Listeria Biofilms

  2026-09-22

  This 2026 study shows that deleting the hly gene weakens Listeria monocytogenes biofilm formation without measurably affecting bacterial growth. The mutant also displayed reduced motility, aggregation, surface hydrophobicity, virulence-associated gene expression, and tolerance to selected ribosome-targeting antibiotics, linking hemolysin biology to persistence in food-related environments.

• PKM2 inhibitor (compound 3k) Workflow Guide

  2026-09-21

  Build cancer-metabolism and immunometabolism assays around a selective pyruvate kinase M2 inhibitor with defined potency, cell-line response, and xenograft precedent. This guide connects aerobic glycolysis disruption in tumor cells with the USP7–PKM2 macrophage pathway while separating established findings from practical optimization recommendations.

• Phosbind Acrylamide for Wheat Kinase Assays

  2026-09-21

  Phosbind Acrylamide provides an antibody-independent route to protein phosphorylation analysis in wheat signaling research. This article translates the TaCKX11-D–TaMPK3/6 findings into a practical SDS-PAGE phosphorylation detection strategy, including controls, interpretation limits, and assay design decisions.

• Vardenafil HCl Trihydrate: PDE5 Assay Guide

  2026-09-20

  Build a connected workflow from biochemical PDE5 inhibition to cGMP signaling, smooth muscle relaxation, and native-membrane proteoform analysis. Vardenafil HCl Trihydrate combines strong enzymatic potency with a practical solubility profile, while careful PDE6 counter-screening helps distinguish target activity from membrane-context effects.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-09-19

  A 2024 ACS Applied Materials & Interfaces study shows that lithium enhances BMSC osteogenesis by increasing exosomal Wnt10a secretion through MARK2-dependent Rab11a/Rab11FIP1 trafficking and subsequent Wnt/β-catenin activation. Lithium-conditioned exosomes and GelMA hydrogels containing these vesicles improved osteogenic responses and bone repair, providing a mechanistic framework for engineering cell-derived therapies.

• Heparin Sodium as a Control in Nanovesicle Assays

  2026-09-18

  Heparin sodium is more than a standard anticoagulant for thrombosis research: it can help investigators interrogate heparan sulfate-dependent nanovesicle uptake while preserving rigorous coagulation controls. This article connects the A5066 reagent to emerging Sertoli-cell nanovesicle research and practical assay design.

• Rosiglitazone: From PPARγ Biology to Translation

  2026-09-18

  Rosiglitazone, also known as Brl-49653, offers a defined way to interrogate PPARγ biology across adipogenesis, insulin sensitivity, and rare lipodystrophy models. This thought-leadership guide connects receptor mechanism with the 2026 characterization of the PPARG R212W variant and provides practical strategies for using Rosiglitazone to distinguish impaired receptor abundance, transcriptional output, mitochondrial dysfunction, and metabolic rescue.

7960 records 1/531 page Next 12345 下5页 Last page